780; p< 0001) being the strongest. Glycoprotein concentrations were also correlated with inflammation markers, mainly hsCRP. Higher glycoprotein concentrations were observed in patients with higher intima media thickness, arterial rigidity and presence of arteriosclerotic plaques. In the multivariate and random forest analyses, the baseline GlycB concentration showed a significant contribution to the detection of FH individuals prone to develop carotid plaques. The concentrations of serum glycoproteins as assessed by H-NMR are robust markers of subclinical inflammation. In FH patients, they are increased in the presence of subclinical vascular damage and could be considered atherosclerosis risk markers in the long term.The concentrations of serum glycoproteins as assessed by 1H-NMR are robust markers of subclinical inflammation. In FH patients, they are increased in the presence of subclinical vascular damage and could be considered atherosclerosis risk markers in the long term.This post hoc analysis was conducted to evaluate the efficacy, tolerability, and health-related quality of life during long-term adjunctive brivaracetam (BRV) treatment in adult patients with focal to bilateral tonic-clonic seizures (FBTCS). Patients (≥ 16 years) were included in this post hoc analysis if they were randomized to BRV or placebo in double-blind, placebo-controlled (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]; core) trials, and received adjunctive BRV in the corresponding long-term follow-up (N01125 [NCT00175916], N01199 [NCT00150800], N01379 [NCT01339559]) trials, and reported FBTCS during the 8-week prospective baseline (core trial). Efficacy (concomitant levetiracetam excluded) and tolerability (concomitant levetiracetam included) were assessed from the first day of BRV in patients who initiated BRV at 50-200 mg/day. Two hundred and eighty-four patients reported FBTCS during baseline (core trials) and were included in the Efficacy Set. Patients (mean age of 37.0 years; 51.8% male; mean epilepsy duration of 22.4 years; median baseline frequency of 2.8 FBTCS per 28 days) received BRV for a median treatment duration of 2.5 years (range 50% of patients reporting a clinically meaningful improvement, were observed in the seizure worry and daily activities/social functioning subscales after 1 and 2 years of BRV treatment. Overall, 278/313 (88.8%; Safety Set) patients reported at least one treatment-emergent adverse event (TEAE), 170 (54.3%) had a drug-related TEAE, 88 (28.1%) had a serious TEAE, and 55 (17.6%) discontinued BRV due to a TEAE. Overall, long-term adjunctive BRV was generally well tolerated and reduced the frequency of FBTCS in adults, with 22.8% of patients (who completed ≥ 1 year of treatment) not reporting any FBTCS during the first year from the first day of BRV treatment. Carbamazepine (CBZ) is one of most used antiepileptic drugs. However, CBZ-resistance is common in patients with epilepsy, and genetic polymorphisms can influence antiepileptic drug responsiveness. The association between the polymorphisms rs3812718 and rs2298771 of theSCN1A gene and risk of resistance to CBZ in epilepsy remains controversial. To further assess the pooled association, we conducted an updated meta-analysis to investigate the contribution of the two SCN1A single nucleotide polymorphisms that may confer CBZ-resistance. We searched PubMed, Embase, and Web of Science databases for eligible studies. All the case-controlled studies related to the association of the SCN1A polymorphisms, rs3812718 and rs2298771, with CBZ-resistance in epilepsy were included. Pooled odds ratios (OR) as well as the corresponding 95 % confidence intervals (CI) were determined. A total of eight out of 255 articles were used to assess the association between SCN1A and CBZ-resistance in epilepsy. We found a significant association between rs2298771 (GG vs GA + AA; OR 3.19, 95 % CI 1.27 - 8.02, p > 0.05, I = 0) and CBZ-resistance in epilepsy patients of Asian ethnicity. No association was observed between the rs3812718 polymorphism and CBZ responsiveness. Our results indicate that Asian patients with epilepsy and the SCN1A rs2298771 polymorphism, especially the GG genotype, may be at risk of CBZ-resistance.Our results indicate that Asian patients with epilepsy and the SCN1A rs2298771 polymorphism, especially the GG genotype, may be at risk of CBZ-resistance. Favorable neurodevelopmental outcomes in epileptic spasms (ES) are tied to early diagnosis and prompt treatment, but uncertainty in the identification of the disease can delay this process. ULK-101 supplier Therefore, we investigated five categories of computational electroencephalographic (EEG) measures as markers of ES. We measured 1) amplitude, 2) power spectra, 3) Shannon entropy and permutation entropy, 4) long-range temporal correlations, via detrended fluctuation analysis (DFA) and 5) functional connectivity using cross-correlation and phase lag index (PLI). EEG data were analyzed from ES patients (n = 40 patients) and healthy controls (n = 20 subjects), with multiple blinded measurements during wakefulness and sleep for each patient. In ES patients, EEG amplitude was significantly higher in all electrodes when compared to controls. Shannon and permutation entropy were lower in ES patients than control subjects. The DFA intercept values in ES patients were significantly higher than control subjects, while DFA exponent values were not significantly different between the groups. EEG functional connectivity networks in ES patients were significantly stronger than controls when based on both cross-correlation and PLI. Significance for all statistical tests was p < 0.05, adjusted for multiple comparisons using the Benjamini-Hochberg procedure as appropriate. Finally, using logistic regression, a multi-attribute classifier was derived that accurately distinguished cases from controls (area under curve of 0.96). Computational EEG features successfully distinguish ES patients from controls in a large, blinded study. These objective EEG markers, in combination with other clinical factors, may speed the diagnosis and treatment of the disease, thereby improving long-term outcomes.These objective EEG markers, in combination with other clinical factors, may speed the diagnosis and treatment of the disease, thereby improving long-term outcomes.